Value of CA 15.3 in breast cancer and comparison with CEA and TPA: A study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis

Breast Cancer Research and Treatment

Volumn 37, Issue 3, 1996, Pages 209-216

  Vizcarra, E ^a,c   Lluch, A ^a   Cibrian R ^b   Jarque, F ^a   Alberola, V ^a   Belloch, V ^a,c   Garcia Conde J ^a  

^a Hosp Clin Univ   (Spain)

^b Department of Physiology ^*  (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Breast cancer; CA 15.3; CEA; Serum markers; TPA; Tumor markers

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; MONOCLONAL ANTIBODY; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 0030034152     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01806502     Document Type: Article

References (34)

1. Stevens D, Mackay IR: Increased carcinoembryonic antigen in heavy cigarette smokers. Lancet ii:1238-1239, 1973
2. Jalanko H, Kuusela P, Roberts P, Sipponen P, Haglund C, Makela O: Comparison of a new tumor marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases. J Clin Pathol 37:218-222, 1984
3. Satake K, Kanazawa G, Kho I, Chung Y, Umeyama K: Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases. Am J Gastroenterol 80: 630-636, 1985
4. Hoskins WJ, Burke TW, Barnhill DR: Tumor-related antigens in gynecologic cancers. In: Ghosh BC , Ghosh L (eds) Tumor Markers and Tumor-Associated Antigens. McGraw-Hill, New York 1987, pp 149-172
5. Novis BH, Gluck E, Thomas P, Steele GD, Zurawski VR Jr, Stewart R, Lavin PT, Zamcheck N: Serial levels of CA 19-9 and CEA in colonic cancer. J Clin Oncol 4:987-993, 1986
6. Busnardo B, Girelli ME, Simioni N, Nacamulli D, Busetto E: Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer 53:278-285, 1984
7. Kjorstad KE, Orjasaefer H: The prognostic significance of carcino-embryonic antigen determinations in patients with adenocarcinoma of the cervix. Gynecol Oncol 19:284-289, 1984
8. Fletcher RH: Carcinoembryonic antigen. Ann Intern Med 104:66-73, 1986
9. Stieber P, Diergarten K, Eiermann W, Albiez M, Fateh-Moghaadam A: CA 15.3: Evaluation and clinical value in breast carcinomas compared with CEA and TPA. In: Klapdor R (ed) New Tumour Markers and Their Monoclonal Antibodies. G Thieme Verlag, New York, 1987, pp 46-51
10. Delarue JC, Mouriesse H, Dubois F, Friedman S, May-Levin F: Markers in breast cancer: Does CEA add to the detection by CA 15.3? Breast Cancer Res Treat 11:273-276, 1988
11. Krebs BP, Pons-Anicet D, Ramaioli A, Galland A, Rossi C, Namer M: Utilité du CA 15.3 dans le cancer du sein. Cancer Commun 2:55-64, 1988
12. Eskelinen M, Tikanoja S, Collan Y: Use of tumor markers CA 15.3, MCA and CEA in breast cancer diagnostics. J Tumor Markers Oncol 4:39-42, 1989
13. Cazin JL, Gosselin P, Boniface B, Demaille MC, Boniface M, Demaille A: Comparative values of several tumour markers: Example of untreated breast carcinoma. Br J Cancer 62:1031-1033, 1990
14. Pons-Anicet D, Krebs BP, Mira R, Namer M: Value of CA 15.3 in the follow-up of breast cancer patients. Br J Cancer 55:567-569, 1987
15. Vilanova C, Pastor MC, Abad-Esteve A, Rosell R, Carles J, Corominas A: Comparison of CA 15.3 and CEA in the clinical course of breast cancer [Abstract]. XVI International ISOBM Congress, Barcelona, p 134, 1988
16. Linares A, Rodrigo L, Garcia S, Valerdiz S, Rodriguez M, Perez R, Garcia R, Sanchez JL, Alonso JL, Arribas JM: Marcadores tumorales en el aparato digestivo: Antigeno polipeptidico histico (TPA). Jano 637:47-49, 1984
17. Inoue M, Inoue Y, Hiramatsu K, Ueda G: The clinical value of tissue polypeptide antigen in patients with gynecologic tumor. Cancer 55:2618-2623, 1985
18. Oehr P, Adolphs HD, Altmann R: Clinical use of TPA in cancer of the urinary bladder using CEA for comparison. In: Peeters H (ed) Protides in Biological Fluids. Pergamon Press, Oxford, 1984, pp 483-486
19. Gion M, Mione R, Dittadi R, Fasan S, Pallini A, Bruscagnin G: Carcinoembryonic antigen ferritin and tissue polypeptide antigen in serum and tissue. Cancer 57:917-922, 1986
20. Nicolini A, Capri A, Di Marco G, Giuliani L, Giordani R, Palla S: A rational postoperative follow-up with carcinoembryonic antigen, tissue polypeptide antigen, and urinary hydroxyproline in breast cancer patients. Cancer 63:2037-2046, 1989
21. Barak M, Steiner M, Finkel B, Abrahamson J, Antal S, Gruener N: CA 15.3, TPA and MCA as markers for breast cancer. Eur J Cancer 26:577-580, 1990
22. Tobias R, Rothwell C, Wagner J, Green A, Liu YSV: Development and evaluation of a radioimmunoassay for the detection of a monoclonal antibody defined breast tumor associated antigen 115D8/DF3 [Abstract 434]. Clin Chem 31:986, 1985
23. Hilkens J, Hilgers J, Buijs F, Hageman PH, Schol D, Van Doornewaard G, Van Den Tweel J: Monoclonal antibodies against human milk fat globule membranes useful in carcinoma research. In: Peeters H (ed) Protides in Biological Fluids. Pergamon Press, Oxford, 1983, pp 1013-1016
24. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J: Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 3:223-232, 1984
25. Miserez AR, Günes I, Müller-Brand J, Walther E, Fridrich R, Macke H: Clinical value of a mucin-like carcinoma-associated antigen in monitoring breast cancer patients in comparison with CA 15.3. Eur J Cancer 27:126-131, 1991
26. Hayes DF, Zurawsky VR, Kufe DW: Comparison of circulating CA 15.3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 4:1542-1550, 1986
27. Colomer R, Ruibal A, Genolla J, Rubio D, Del Campo JM, Bodi R, Salvador L: Circulating CA 15.3 levels in the post surgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res Treat 13:123-133, 1989
28. Silver HKB, Archibald BL, Ragaz J, Coldman AJ: Relative operating characteristic analysis and group modeling for tumor markers: Comparison of CA 15.3 carcinoembryonic antigen, and mucin-like carcinoma-associated antigen in breast cancer. Cancer Res 51:1904-1909, 1991
29. Vizcarra E: Marcadores tumorales CA 15.3, CEA y TPA en el cáncer de mama. Doctoral Thesis, University of Valencia, Spain, ISBN: 84-370-0610-4, 1989
30. Viedma JA: Métodos estadísticos. Fundamentos y aplicaciones. Ed. del Castillo, Madrid, 1972
31. Krebs BP, Pons-Anicet D, Namer N: CA 15.3 in breast cancer: A more specific and sensitive marker than carcinoembryonic antigen (CEA). In: Klapdor R (ed) New Tumour Markers and Their Monoclonal Antibodies. G Thieme Verlag, New York, 1987, pp 60-64
32. Ingersleben G, Souchon R, Brand U, Fitzner R: CA 15.3 in comparison with CEA in the follow-up and therapy control of breast carcinoma. New aspects. In: Klapdor R (ed) New Tumour Markers and Their Monoclonal Antibodies. G Thieme Verlag, New York, 1987, pp 113-117
33. Hayes DF, Kiang DT, Korzun AH, Tondini C, Wood WC, Kufe DW: CA 15.3 and CEA spikes during chemotherapy for metastatic breast cancer [Abstract]. Proc Am Soc Clin Oncol 7:38, 1988
34. Colomer R, Ruibal A, Salvador L: Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 64: 1674-1681, 1989